UNSPSC 51162100: Combination antituberculars

This classification denotes combination drugs used in the treatment of tuberculosis, any of the infectious diseases of man and other animals caused by species of mycobacterium. such drugs are divided into two main classes: first-line agents, those with the greatest efficacy and acceptable degrees of toxicity used successfully in the great majority of cases; and second-line drugs used in drug-resistant cases or those in which some other patient-related condition has compromised the effectiveness of primary therapy.

Typical combination antitubercular constituents are isoniazid, pyrazinamide, pyridoxine, and rifampin.

UNSPSC 51162100 Combination antituberculars is a Class code, but the recent state and local opportunities posted under it do not consistently reflect procurement of antitubercular pharmaceuticals. Instead, the code captures a fragmented mix of health-related services and supplies: Seminole County, Florida is procuring naloxone and drug deactivation systems for community health delivery; the Utah Department of Health and Human Services is funding housing services for individuals experiencing homelessness with active tuberculosis through a sole-source award to Wasatch Homeless Health Care; and Hall County, Georgia is seeking an on-site pharmacy services provider to manage prescription dispensing for county employees and retirees. The issuing bodies are county health and human services departments and local government family health centers, reflecting the clinical or administrative reach of county-level public health operations. The code shows limited focus on pharmaceutical procurement per se and instead bundles tuberculosis-related housing, naloxone distribution, and general pharmacy operations under a single classification.

Activity appears concentrated in the Southeast, with recent opportunities from Seminole County (Florida) posting in June 2026 with a response deadline of July 26, 2023, Hall County (Georgia) posting in May 2026 with a June 4, 2026 deadline, and the Utah Department of Health and Human Services posting a sole-source notice in June 2026 with a June 26, 2026 challenge period. The Florida naloxone procurement is an IFB for 1,900 units of naloxone and 800 safe drug deactivation systems annually with quarterly deliveries required; the Utah award is Amendment 4 to an ACWESPP sole-source contract increasing funding to $186,044 total for TB housing through June 30, 2027; and the Georgia RFQ/P #47-010 seeks a single pharmacy services provider to serve approximately 3,005 eligible individuals, with technical and cost evaluation weighted 80/20 and contract award on January 1, 2027. The scope mismatch between the code's antitubercular pharmaceutical intent and the actual health services mix suggests the code may be misapplied in state and local systems or reflects informal classification practices that diverge from UNSPSC intent.